ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PRM Proteome Sciences Plc

3.53
-0.07 (-1.94%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.07 -1.94% 3.53 3.06 4.00 - 77,800 16:35:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 7.78M 1.33M 0.0045 8.00 10.63M
Proteome Sciences Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 3.60p. Over the last year, Proteome Sciences shares have traded in a share price range of 2.97p to 8.50p.

Proteome Sciences currently has 295,182,056 shares in issue. The market capitalisation of Proteome Sciences is £10.63 million. Proteome Sciences has a price to earnings ratio (PE ratio) of 8.00.

Proteome Sciences Share Discussion Threads

Showing 157451 to 157472 of 157525 messages
Chat Pages: 6301  6300  6299  6298  6297  6296  6295  6294  6293  6292  6291  6290  Older
DateSubjectAuthorDiscuss
10/4/2024
11:24
There are very, very few crumbs of comfort to be taken from the results.

Line after line it is repeated that each and every sales sector was 'Challenging'

As for the US start up, perhaps the timing couldnt have been more wrong?

"It was a challenging year in our service business in 2023. As in previous years, the US is by far our most significant market in terms of biopharma companies who outsource their proteomic services to Contract Research Organisations ("CROs") such as Proteome Sciences. Unfortunately, the biopharma market especially in the US was marked by employee layoffs in 2023. According to Fierce Biotech, a company that provides news, analysis and data relating to the biotech sector, biopharma layoffs were 57% up in 2023. This has been confirmed by other Life Science provider companies in their public reporting. The significantly reduced level of financing in biopharma resulted in workforce reductions affecting 187 organisations in 2023. We were in contact and discussing projects with 38 of these that were primarily focused in proteomic pre-clinical and clinical research. Projects were either cancelled before samples were shipped, or significantly delayed pending future financing rounds. This seriously affected our ability to win business."

barry evans
10/4/2024
11:12
We knew the number would be poor as it was flagged earlier, and we also knew that the expences of establishing a presence in America would be high. For myself I am pleased that we are in our biggest market.
I am hopeful of the upcomibg stroke test and the real potential of Alzimers especially after the anounced reserch going on in Oxford. In addition the development of new products provides some comfort to me.

wellhonedhutch
10/4/2024
10:13
Someone been on the crack pipe over the other thread.
peverill
10/4/2024
10:08
It is quite sobering to think that there is actually a person IRL that has created the avatars pool2 and wasjobber.
monte1
10/4/2024
10:03
59704 see 59703
barry evans
10/4/2024
10:02
wasjobber,

Thermo have been a long term partner of Proteome Sciences for 15 years, but I agree it'll be good to see Thermo taking a more prominent position. After reading the RNS this morning, the future looks brighter than ever.

You've already mentioned what I think is probably the most significant RNS statement:-

"It's very interesting that PRM are now openly stating that their patented Alzheimer's and cancer biomarkers may be critical to new diagnostics and treatment moving forward.

STRONG BUY"

It's very significant for Proteome Sciences to say that.

The value of these biomarkers will be considerable and will project PRM into the £100 millions plus market cap. with ease.

I think you are now correct, we are at a pivotal moment for the share price and investors buying now will achieve significant returns, possibly quicker than some may think.

pools2
10/4/2024
09:18
Grow up! It was a catastrophic performance with the business having gone badly backwards, there is no other way of looking at it.
barry evans
10/4/2024
09:15
It looks like Thermo are getting more involved with PRM.

"We continue to innovate in chemistry and will be working on ancillary products to add new functionality for TMTproTM enabled studies through a sponsored research project."

wasjobber
10/4/2024
09:01
Riiiiiiiiiichard?
barry evans
10/4/2024
08:49
Absolutely pitiful.
monte1
10/4/2024
08:49
Get thee to a nunnery.
monte1
10/4/2024
08:28
It's very interesting that PRM are now openly stating that their patented Alzheimer's and cancer biomarkers may be critical to new diagnostics and treatment moving forward.

STRONG BUY

wasjobber
10/4/2024
07:45
My 6p target looks like a stretch for this year!
W41

wrighty41
10/4/2024
07:15
What are they doing ??
peverill
09/4/2024
08:42
“ He Has retired.”
Was there an announcement?
All seems a bit rushed

sandcrab2
09/4/2024
07:11
Where are the results???,pure shambles of a company and getting worse as time goes by.
peverill
08/4/2024
11:19
The trades look like Bed & ISA's to start the new tax year.

Definitely some type of 'put through' and completely market neutral.

It's a sign of confidence from investors.

wasjobber
08/4/2024
11:16
Someone has run out of patience!!
W41

wrighty41
07/4/2024
15:12
He Has retired.
littlejohn277
07/4/2024
13:18
Anyone know what's happened to the Michael Walters Web site?
sandcrab2
06/4/2024
15:50
2M @ 2.6p wouldn't help much with my tax
mashman
06/4/2024
01:06
Tuco, tax.
chutes01
Chat Pages: 6301  6300  6299  6298  6297  6296  6295  6294  6293  6292  6291  6290  Older

Your Recent History

Delayed Upgrade Clock